Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) is 36.06% higher on its value in year-to-date trading and has touched a low of $4.03 and a high of $8.88 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BCRX stock was last observed hovering at around $7.96 in the last trading session, with the day’s gains setting it 0.19%.
Currently trading at $8.15, the stock is 0.87% and 5.73% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.92 million and changing 2.39% at the moment leaves the stock 32.03% off its SMA200. BCRX registered 6.54% gain for a year compared to 6-month gain of 48.99%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 4.22% loss in the last 1 month and extending the period to 3 months gives it a 32.52%, and is 5.16% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.93% over the week and 3.75% over the month.
Biocryst Pharmaceuticals Inc. (BCRX) has around 536 employees, a market worth around $1.69B and $382.24M in sales. Profit margin for the company is -38.18%. Distance from 52-week low is 102.23% and -8.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-42.50%).
The EPS is expected to grow by 64.95% this year
322.0 institutions hold shares in Biocryst Pharmaceuticals Inc. (BCRX), with institutional investors hold 87.62% of the company’s shares. The shares outstanding are 205.77M, and float is at 195.77M with Short Float at 12.29%. Institutions hold 86.61% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 19.96 million shares valued at $123.33 million. The investor’s holdings represent 9.6845 of the BCRX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 18.77 million shares valued at $116.0 million to account for 9.1086 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 12.57 million shares representing 6.1 and valued at over $77.68 million, while STATE STREET CORP holds 4.5359 of the shares totaling 9.35 million with a market value of $57.76 million.
Biocryst Pharmaceuticals Inc. (BCRX) Insider Activity
The most recent transaction is an insider sale by McKee Amy E, the company’s Director. SEC filings show that McKee Amy E sold 8,600 shares of the company’s common stock on Jun 24 ’24 at a price of $6.32 per share for a total of $54352.0. Following the sale, the insider now owns 27831.0 shares.
Biocryst Pharmaceuticals Inc. disclosed in a document filed with the SEC on Jun 17 ’24 that SANDERS MACHELLE (Director) sold a total of 4,689 shares of the company’s common stock. The trade occurred on Jun 17 ’24 and was made at $6.00 per share for $28134.0. Following the transaction, the insider now directly holds 27742.0 shares of the BCRX stock.
Still, SEC filings show that on Jun 14 ’24, HEGGIE THERESA (Director) disposed off 6,698 shares at an average price of $6.11 for $40925.0. The insider now directly holds 52,852 shares of Biocryst Pharmaceuticals Inc. (BCRX).
